menu
    • menu
    [{"orgOrder":0,"company":"Alimentiv","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase II","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Alimentiv \/ Abbott Laboratories"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase IV","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Alimentiv \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Phase IV","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alimentiv \/ Undisclosed"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Alimentiv","highestDevelopmentStatusID":"11","companyTruncated":"Alimentiv \/ Alimentiv"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Avobis Bio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Alimentiv \/ Alimentiv","highestDevelopmentStatusID":"8","companyTruncated":"Alimentiv \/ Alimentiv"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Avobis Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Alimentiv","highestDevelopmentStatusID":"1","companyTruncated":"Alimentiv \/ Alimentiv"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Exeliom Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EXL01","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Alimentiv","highestDevelopmentStatusID":"6","companyTruncated":"Alimentiv \/ Alimentiv"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MB-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Alimentiv \/ Alimentiv","highestDevelopmentStatusID":"6","companyTruncated":"Alimentiv \/ Alimentiv"},{"orgOrder":0,"company":"Alimentiv","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Alimentiv","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alimentiv \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Alimentiv \/ Takeda Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Alimentiv

    Menu

    Alimentiv

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirikizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-Label Study of Mirikizumab Efficacy in CD Patients with Inflammatory Strictures

                            Details : Mirikizumab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 31, 2025

                            Lead Product(s) : Mirikizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : Avobis Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tiss...

                            Details : AVB-114 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Perianal Fistula-associated with Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 19, 2024

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : Avobis Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MB-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Mage Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants

                            Details : MB-001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 12, 2024

                            Lead Product(s) : MB-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Mage Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vedolizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

                            Details : Vedolizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 14, 2024

                            Lead Product(s) : Vedolizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infliximab

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Recipient : University of Calgary

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominan...

                            Details : Infliximab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : Infliximab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Recipient : University of Calgary

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXL01

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Exeliom Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate ...

                            Details : EXL01 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 15, 2022

                            Lead Product(s) : EXL01

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Exeliom Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Avobis Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

                            Details : AVB-114 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rectal Fistula.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 19, 2021

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Avobis Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Determination of the Optimal Treatment Target in Ulcerative Colitis

                            Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 06, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Alimentiv

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Abbott Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

                            Details : Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            October 29, 2012

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Abbott Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth